OTC antihistamines
This article was originally published in The Tan Sheet
Executive Summary
Nonprescription Drug Manufacturers Association submits a study to FDA on March 3 that NDMA says supports the efficacy of doxylamine (7.5 mg q.i.d. for two days) in relieving runny nose and sneezing associated with the common cold. According to NDMA, the new study, in conjunction with previously submitted antihistamine studies, adds further support for the efficacy of all antihistamines in treating common cold symptoms. NDMA also reiterated its request for an "OTC feedback"" meeting to discuss the antihistamine submissions ("The Tan Sheet" March 15, 1993, In Brief
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning